TONMYA demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT study. Unique sublingual formulation designed for bedtime dosing bypa ...
Neurologists participating in the survey also reported growing dissatisfaction with available treatment options as Parkinson’s disease progresses. Physicians estimated that approximately 45% of their ...
PsyPost on MSN
Scientists reveal atypical depression is a distinct biological subtype linked to antidepressant resistance
A new genetic and clinical analysis suggests that atypical depression represents a distinct biological subtype of the ...
DENVER, CO / ACCESS Newswire / January 20, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central ...
SNRIs help with depression and anxiety by stopping the reuptake of serotonin and norepinephrine. Common SNRIs include Cymbalta, Effexor, and Pristiq, which are used for different disorders. Duloxetine ...
CHATHAM, N.J., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated commercial biotechnology company, today announced ...
TONMYA is a unique, non-opioid, once-daily bedtime analgesic that significantly reduces fibromyalgia pain and is generally well-tolerated "The availability of TONMYA is a momentous day for Tonix, ...
Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. Analyses of nationwide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results